You are here

Extended Release of Pyridostigmine Bromide for Effectively Combating Nerve Agent Exposure

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-C-0200
Agency Tracking Number: C181-004-0004
Amount: $149,999.91
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD181-004
Solicitation Number: 2018.0
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-10-01
Award End Date (Contract End Date): 2019-03-31
Small Business Information
2531 West 237th Street, Suite 127, Torrance, CA, 90505
DUNS: 114060861
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Dr. Anamika Ray
 (310) 530-2011
Business Contact
 Dr. Kisholoy Goswami
Phone: (310) 530-2011
Research Institution
Chemical warfare agents such as the lethal nerve agent soman are a major source of risk to military personnel. Currently, pyridostigminebromide (PB) is the only FDA-approved pretreatment to counteract the effects of soman. The rationale behind PB administration is that it actsas a temporary inhibitor of AChE. This precludes nerve agents from irreversible inactivation of AChE, thereby mitigating the risks. To aidmilitary personnel, improved and stable formulations of PB are required to withstand higher desert temperature with sustained and uniformrelease and less frequent dosing. To address this need, InnoSense LLC in collaboration with Oklahoma State University will develop ananocellulose encapsulated PB (nCAP-PB) which can be used orally. Phase I efforts will include drug delivery system formulation, loadingmeasurement, in vitro drug release profile characterization, stability measurements and in vivo characterization in mice. In Phase II, InnoSensewill optimize the formulation, process and perform additional functionalization and scale up the prototype formulation.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government